Trials Confirm Lorundrostat Effectively Lowers Blood Pressure

Aldosterone synthase inhibitor may offer a new option for patients with resistant or uncontrolled hypertension

Topline

Lorundrostat, a novel aldosterone synthase inhibitor, significantly reduced systolic blood pressure in patients with uncontrolled or resistant hypertension across two pivotal trials, supporting its potential as a next-generation add-on therapy.

Study Details

Mineralys Therapeutics recently announced positive topline results from two major clinical …